This poor clinical outcome in breast cancers with Th17 cell accumulation was shown to be associated with the inhibition of CD4+ cell and CD8+ cell activation, thus limiting anti-tumor immune reactivity [31]. The gene discussed is CD4; the disease is neoplasm.